in-PharmaTechnologist presents its latest round-up of new appointments in the pharmaceutical industry, including news from Lanthes, Provectus and Achillon.
Lantheus Medical Imaging has boosted its regulatory and quality capabilities with the appointment of two new VPs.
Alex Kuta as VP of global regulatory affairs, and Nigel Williams as VP of quality.
In his new role, Kuta will liase with the regulatory agencies to ensure operations are compliant.
Williams will work with him to ensure quality standards are met.
The diagnostics imaging company also drafted Sam Leno in as chairman of the audit committee, and member of the board.
He takes on his new role after retiring from Boston Scientific last year, where he served as chief operations officer.
Don Kiepert, president and CEO at Lantheus said: “Sam’s extensive financial and operational experience will be a great asset to our board and to the company's strategic planning and operations."
Provectus Pharmaceuticals has shuffled its board in a bid to trade on the national stock market.
President of investment firm GoStar Jan Koe has been placed on the board, and Provectis’ Eric Wachter will leave.
Wachter will now take on the newly created position of chief technology officer for the firm.
The move means the company now meets NASDAQ corporate governance requirements, which calls for a majority of independent directors.
Craig Dees, CEO, said: “As a business leader, Jan Koe has experience serving on the board of a public company, and will be an important asset to us as we prepare Provectus for a potential move to listing on a national stock market.”
Achillion Pharmaceuticals has named Gautam Shah its new executive VP.
Previously senior VP, Shah will also continue to work as the firm’s chief compliance officer.
President and CEO Michael Kishbauch said: “Aided by the strong working relationships he has cultivated with the regulatory agencies, his tenure has been marked by significant accomplishments including regulatory submissions for all four of our clinical HCV programs and advancements in the formulation and manufacturing of our compounds."
Dennis Molnar has become Paratek Pharmaceuticals’ CEO and director.
Formerly Paratek’s VP of corporate development, Molnar succeeds Thomas Bigger, who resigned earlier this year.
The company has also hired Pfizer vet Evan Loh as chief medical officer.
Molnar said: "We are excited about the addition of Dr. Loh as chief medical officer, and we look forward to the next chapter of the company's development with his involvement."
Granules India has a named VVS Murthy as its new CFO.
He takes the role after working as CFO for Dishman Pharmaceuticals.
Murthy previously served as Group Chief Financial Officer at Dishman Pharmaceuticals and Chemicals Ltd. and has over 32 years of experience in the Finance industry including 17 years in the Pharmaceutical Industry.
“The addition of Mr. Murthy to the senior management team will ensure that we are able to move quickly and capitalise on new opportunities,” said Krishna Prasad, MD.
“Mr. Murthy’s knowledge in optimizing financial systems, working with foreign subsidiaries and M&A experience will be beneficial as our company continues to grow.”
Teva Pharmaceuticals has re-elected Phillip Frost as chairman of the board for another three year term.
He has served as chairman since March 2010, promoted from the vice chair position he held from 2006.
Moshe Many, vice chairman said: “Dr. Phillip Frost has the Board's full support. We would continue to benefit from his vision and guidance.”